The renin-angiotensin-aldosterone system: RAAS physiology, hypertension, and ACE-inhibitor therapy

Intuition Beginner

The kidneys filter blood, but they also monitor blood pressure. When pressure drops, when the sodium level in the blood falls, or when the sympathetic nervous system activates, specialised cells on the wall of the kidney's afferent arteriole release an enzyme called renin into the bloodstream. Renin is a biochemical alarm — its release signals that the body must raise blood pressure to protect perfusion of the brain, the heart, and the kidney itself.

Renin starts a chain reaction. It clips a liver-made protein called angiotensinogen into a short ten-amino-acid peptide called angiotensin I. An enzyme on the lining of the lungs and kidneys, called ACE (angiotensin-converting enzyme), then clips angiotensin I further into the active eight-amino-acid peptide angiotensin II. Angiotensin II does three things: it constricts blood vessels, it triggers the adrenal gland to release aldosterone (which makes the kidney retain sodium and water), and it acts on the brain to make you thirsty.

Together this chain is the renin-angiotensin-aldosterone system, or RAAS. It is the body's long-term blood-pressure regulator. When the RAAS is overactive — from a narrowed renal artery, a renal tumour, or the chronic low-grade activation of essential hypertension — blood pressure stays high. Hypertension affects roughly one in three adults worldwide and is the single largest contributor to preventable death from heart attacks, strokes, and kidney failure. Drugs that block the RAAS — ACE inhibitors (captopril, lisinopril, ramipril) and ARBs (losartan, valsartan) — are first-line antihypertensive therapy.

Visual Beginner

The defining picture is a chain with four links running from the kidney to the body's blood vessels and back to the kidney. The kidney (left) releases renin in response to low blood pressure, low sodium delivery to the macula densa, or sympathetic activation. Renin clips liver-derived angiotensinogen to angiotensin I, and ACE on the pulmonary endothelium then clips angiotensin I to angiotensin II.

Angiotensin II acts at AT1 receptors on blood vessels (vasoconstriction), on the adrenal zona glomerulosa (aldosterone release), and on the brain (thirst, ADH release). Aldosterone acts at the distal tubule to retain sodium and water, expanding blood volume. A parallel counter-regulatory arm — ACE2 converting angiotensin II to angiotensin 1-7, which acts at the Mas receptor to vasodilate — is drawn as a side branch.

A second picture is the cellular architecture of the juxtaglomerular apparatus: the afferent arteriole (with its renin-secreting granular cells), the glomerulus, and the macula densa plaque of specialised tubular cells at the start of the distal tubule that signals back to the arteriole. The juxtaglomerular apparatus is the sensory organ that closes the feedback loop, integrating pressure, sodium, and sympathetic signals into a single renin-secretion output.

Worked example Beginner

In 1965 the Brazilian physiologist Sérgio Ferreira, working at the Butantan Institute in São Paulo, was studying the venom of the jararaca snake (Bothrops jararaca). He found a family of small peptides in the venom that potentiated the vasodilator bradykinin and, unexpectedly, also inhibited an enzyme in the lung that converts angiotensin I to angiotensin II. Ferreira called this fraction the bradykinin-potentiating factor (BPF). One of the peptides, teprotide (a nonapeptide), was later isolated and tested in human volunteers — it lowered blood pressure in hypertensive patients, but only by injection, not as a pill.

In 1977, scientists at Squibb — Miguel Ondetti, Bernard Rubin, and David Cushman — used the structure of Ferreira's venom peptides as a template to design a small molecule that would bind the active-site zinc of ACE. They added a sulfhydryl group to chelate the zinc ion directly, producing a molecule small enough to be absorbed orally: captopril (capto- for the capturing sulfhydryl; -pril for the enzyme-inhibitor suffix that became the drug-class hallmark). Captopril became the first orally-active ACE inhibitor to reach market, approved by the FDA in 1981.

Step 1. Captopril blocks Ang I to Ang II conversion. With Ang II suppressed, blood vessels relax (vasoconstriction arm) and aldosterone falls (volume arm). Both arms lower blood pressure.

Step 2. In the first clinical trials in patients with severe hypertension (diastolic above 110 mmHg), captopril reduced systolic pressure by approximately 25 mmHg and diastolic by 15 to 20 mmHg over 4 to 8 weeks of therapy — comparable to or better than existing diuretic and beta-blocker regimens, with fewer side effects in most patients. A dry cough appeared in roughly 10 percent of patients, the signature ACE-inhibitor side effect.

What this tells us: a single evolutionary molecule from a South American pit viper, read out by structure-based drug design, produced the first-in-class medicine that defined twentieth-century hypertension therapy. Captopril's design — a zinc-chelating sulfhydryl guided by Bothrops jararaca's venom peptides — is a canonical example of "nature as pharmacologist."

Check your understanding Beginner

Formal definition Intermediate+

The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that regulates mean arterial pressure and extracellular-fluid volume through a coordinated sequence of enzymatic reactions and receptor-mediated end-organ effects ^{[Boron-Boulpaep 2017]}. The cascade proceeds in six steps.

Step 1: renin release at the juxtaglomerular apparatus

Juxtaglomerular (JG) granular cells on the wall of the afferent arteriole synthesise, store, and release renin (a 340-amino-acid aspartyl protease; gene REN) in response to three convergent signals. (a) Intrarenal baroreceptor. A fall in renal perfusion pressure is sensed directly by the JG cells themselves, which behave as stretch-sensitive mechanoreceptors — reduced stretch depolarises them and triggers exocytosis of renin-containing dense granules. (b) Macula densa NaCl sensing. A fall in NaCl delivery to the macula densa (the plaque of specialised tubular cells at the start of the distal tubule, in close apposition to the afferent arteriole). The macula densa signals via prostaglandins PGE2 and PGI2, which diffuse to the adjacent JG cells and raise intracellular cAMP. (c) Beta-1 adrenergic stimulation. Sympathetic input via renal nerves activates beta-1 receptors on JG cells, raising cAMP and triggering renin exocytosis. The three signals converge on cAMP, the common second messenger for renin secretion.

Step 2: angiotensinogen to angiotensin I

Renin cleaves the Leu-10–Val-11 bond of angiotensinogen, a 453-amino-acid alpha-2-globulin constitutively released by the liver (and induced by glucocorticoids, oestrogens, thyroid hormone, and Ang II itself). The product is the decapeptide angiotensin I (Ang I; sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu). Ang I is biologically inactive at physiological concentrations.

Step 3: angiotensin I to angiotensin II via ACE

Angiotensin-converting enzyme (ACE; EC 3.4.15.1, also called kininase II; gene ACE) is a zinc-containing dipeptidyl carboxypeptidase located predominantly on the luminal surface of pulmonary endothelial cells (also kidney, gut, brain, and testis). ACE cleaves the C-terminal His-Leu dipeptide from Ang I, generating the active octapeptide angiotensin II (Ang II; Asp-Arg-Val-Tyr-Ile-His-Pro-Phe). ACE also degrades bradykinin to inactive fragments — the dual-substrate specificity that explains the ACE-inhibitor cough and angioedema.

Step 4: Ang II receptor signalling

Ang II signals at two G-protein-coupled receptors. AT1 (AGTR1; Gq/11-coupled; the dominant pathophysiological receptor) mediates vasoconstriction (via phospholipase C, IP3, and intracellular Ca2+ in vascular smooth muscle), aldosterone synthesis and secretion (adrenal zona glomerulosa), sympathetic activation (presynaptic facilitation at postganglionic neurons), ADH release and thirst stimulation (hypothalamus), reactive-oxygen-species generation (NADPH oxidase), and pro-fibrotic, pro-growth effects in cardiac and vascular tissue. AT2 (AGTR2; Gi-coupled; counter-regulatory) mediates vasodilation (via bradykinin and nitric oxide), anti-growth, anti-fibrotic, and pro-differentiation effects; it is upregulated in tissue injury and during fetal development.

Step 5: aldosterone synthesis and renal action

Ang II (and elevated serum K+) acts at AT1 receptors on zona glomerulosa cells of the adrenal cortex to stimulate aldosterone synthase (CYP11B2), the rate-limiting enzyme in aldosterone biosynthesis from cholesterol. Aldosterone is secreted into the blood and acts at the distal nephron (distal convoluted tubule, connecting tubule, and cortical collecting duct principal cells) on the mineralocorticoid receptor (MR; NR3C2), a nuclear receptor that transcriptionally upregulates ENaC sodium-channel subunits (alpha, beta, gamma) and the basolateral Na+/K+-ATPase. Result: sodium reabsorption from tubular fluid (raising extracellular-fluid volume and blood pressure), coupled to potassium and hydrogen-ion excretion.

Step 6 (counter-regulatory arm — ACE2)

Angiotensin-converting enzyme 2 (ACE2; EC 3.4.17.23; gene ACE2) is a monocarboxypeptidase that cleaves Ang II to the heptapeptide angiotensin 1-7 (Ang 1-7). Ang 1-7 acts at the Mas receptor (a GPCR encoded by MAS1) to produce vasodilation, anti-fibrosis, anti-proliferation, and anti-inflammation — functionally opposing the AT1 arm. ACE2 also cleaves Ang I to the inactive Ang 1-9. ACE2 is the cell-surface receptor that SARS-CoV-2 uses for cell entry (Hoffmann 2020, Cell 181:1481), a fact that dominated the early COVID-19 pharmacology debate about whether to continue ACE inhibitors and ARBs in infected patients.

Counterexamples to common slips

• Renin directly raises blood pressure. No. Renin is a rate-limiting enzyme with no vasoactive effect of its own at physiological concentrations. Sustained BP elevation requires downstream Ang II and aldosterone. Infusing renin alone into a nephrectomised animal (no liver angiotensinogen response, no Ang II generation) produces no pressor effect.

• ACE's only product is Ang II. No. ACE also degrades the vasodilator bradykinin (and substance P). The dual specificity is the molecular reason ACE inhibitors cause dry cough (bradykinin accumulation) and the rare but serious angioedema. ARBs, which block AT1 directly without inhibiting ACE, do not share this side-effect profile.

• Ang II is harmful. Oversimplified. Ang II is essential for minute-to-minute BP regulation — posture change, exercise, and the response to haemorrhage all depend on acute Ang-II-mediated vasoconstriction. The pathogenic regime is chronic over-activation, which drives sustained hypertension, cardiac fibrosis, and progressive renal injury.

• ACE inhibitors and ARBs are clinically equivalent. Close but not interchangeable. ACE inhibitors block Ang II formation (and raise bradykinin — cough and angioedema risk); ARBs block AT1 directly (allowing Ang II to still act at the counter-regulatory AT2). ARBs are preferred in patients with cough or angioedema; ACE inhibitors have a small outcome advantage in post-myocardial-infarction left-ventricular dysfunction (SAVE, TRACE, AIRE trials) and are cheaper as generics.

• Aldosterone acts only on the kidney. No. Aldosterone has direct cardiac and vascular effects via the mineralocorticoid receptor, driving fibrosis and hypertrophy. Mineralocorticoid-receptor antagonists (spironolactone, eplerenone) reduce cardiac fibrosis and mortality independent of blood pressure — the content of the RALES (1999) and EMPHASIS-HF (2011) trials in heart failure.

• ACE2 is a subtype of ACE. No. ACE and ACE2 are different gene products (17 percent sequence identity), with different catalytic activities (dipeptidyl- versus monocarboxy-peptidase), different substrates, and different products. ACE2 generates the protective Ang 1-7 arm, which is the reason SARS-CoV-2 binding and internalising ACE2 has complex consequences for the system beyond simple "RAAS over-activation."

Key mechanism: the RAAS cascade and therapeutic targeting Intermediate+

Mechanism (the dual-arm blood-pressure set-point). Mean arterial pressure $P$ factors into cardiac output $Q$ and total peripheral resistance $R$: $P=Q\cdot R$. The RAAS controls both arms. Aldosterone-driven sodium retention expands extracellular-fluid volume $V$, which raises venous return and hence cardiac output by the Frank-Starling mechanism: $Q=Q_0+\alpha (V-V_0)$ with $\alpha >0$. Ang II acting at AT1 receptors constricts resistance vessels: $R=R_0(1+\beta A_{\mathrm{Ang}})$ with $\beta >0$ and $A_{\mathrm{Ang}}$ the plasma Ang II concentration. Inhibition at any of four points in the cascade — renin (aliskiren), ACE (captopril, lisinopril, ramipril), the AT1 receptor (losartan, valsartan), or the mineralocorticoid receptor (spironolactone, eplerenone) — reduces steady-state blood pressure by disrupting one or both arms of the $P=Q\cdot R$ identity.

Derivation. Let renal sodium excretion at fixed glomerular filtration rate obey $E=E_0-\delta A$, where $A$ is plasma aldosterone and $\delta >0$ parameterises ENaC-mediated reabsorption in the distal nephron. Let dietary sodium intake be $I$ (mmol/day). Then total body exchangeable sodium $N$ obeys

$$\dot{N}=I-E=I-E_0+\delta A.$$

Extracellular-fluid volume scales with body sodium: $V=V_0+\gamma N$ with $\gamma >0$. Aldosterone is driven by Ang II via the adrenal cortex: $A=A_{\mathrm{base}}+ϵA_{\mathrm{Ang}}$ with $ϵ>0$. At steady state, $\dot{N}=0$ gives $A^{\ast }=(E_0-I)/\delta$, hence

$$A_{\mathrm{Ang}}^{\ast }=\frac{A^{\ast }-A_{\mathrm{base}}}{ϵ}=\frac{E_0-I-\delta A_{\mathrm{base}}}{\delta ϵ}.$$

The steady-state volume satisfies $V^{\ast }=V_0+\gamma N^{\ast }$, and substituting into $P^{\ast }=Q(V^{\ast })\cdot R(A_{\mathrm{Ang}}^{\ast })$ gives

$$P^{\ast }=(Q_0+\alpha (V^{\ast }-V_0))\cdot R_0(1+\beta A_{\mathrm{Ang}}^{\ast }).$$

This is the closed-loop steady-state mean arterial pressure as a function of the RAAS gains $\alpha ,\beta ,\gamma ,\delta ,ϵ$ and the dietary intake $I$.

Pharmacological consequences. An ACE inhibitor reduces $A_{\mathrm{Ang}}^{\ast }$ toward zero (the renin feedback loop raises renin, but ACE is the rate-limiting step, so $A_{\mathrm{Ang}}^{\ast }$ falls). With $A_{\mathrm{Ang}}^{\ast }$ suppressed, $A^{\ast }=A_{\mathrm{base}}+ϵA_{\mathrm{Ang}}^{\ast }$ falls (lower aldosterone, lower volume arm) and the $R$-arm relaxes (lower resistance). $P^{\ast }$ falls on both arms simultaneously — the mechanistic content of the empirical observation that ACE inhibitors reduce blood pressure in high-renin hypertensive phenotypes within hours and reach steady-state reduction within 2 to 4 weeks. An ARB blocks the $R$-arm directly at the AT1 receptor but leaves Ang II free to act at the AT2 receptor (counter-regulatory vasodilation) — the typical ARB-induced BP reduction is 70 to 90 percent of the equivalent ACE-inhibitor effect, with less cough and angioedema.

Laragh's volume-versus-vasoconstriction framework. Laragh 1973 ^{[Laragh 1973]} observed that hypertensive patients segregate by renin profile into vasoconstriction-mediated (high-renin; respond to ACE inhibitors, ARBs, beta-blockers) and volume-mediated (low-renin; respond to diuretics and MR antagonists) subtypes. The closed-loop expression above makes this precise: when the vasoconstriction gain $\beta$ is large (high-renin phenotype), the $R$-arm dominates and $P^{\ast }$ is sensitive to ACE inhibition. When the aldosterone gain $\delta$ is large (high-aldosterone phenotype, as in primary aldosteronism), the $V$-arm dominates and $P^{\ast }$ is sensitive to diuretics and MR antagonists. Mixed phenotypes — most patients with essential hypertension — respond to either drug class and to combination therapy.

Bridge. The dual-arm closed-loop expression builds toward 18.02.03 pending hemodynamics, where the $P=Q\cdot R$ identity is established for the systemic circulation as Poiseuille-derived vascular resistance, and appears again in 18.07.04 for the analogous endocrine-axis design — the HPT axis, where the thyroid TSH-T3-T4 loop has the same three-tier topology but operates on a slower time scale and through nuclear rather than membrane receptors. The foundational reason the RAAS is the textbook long-term blood-pressure regulator is exactly that it acts on both arms of the $P=Q\cdot R$ identity simultaneously rather than on a single arm: the bridge is the Ang II molecule that coordinates vasoconstriction (resistance) with aldosterone-driven sodium retention (volume), integrating minute-to-minute neural BP control with hour-to-day renal volume control into a single hormonal response. Putting these together identifies the Laragh volume-versus-vasoconstriction framework with the choice of which arm of the closed-loop expression to perturb pharmacologically, and the same feedback architecture generalises to every endocrine axis in clinical medicine — the HPA axis (CRH-ACTH-cortisol), the gonadal axis (LH/FSH-sex-steroids), and the calcium-PTH axis. The central insight is that closed-loop multi-tier endocrine control identifies a single regulated variable (here $P^{\ast }$) with the joint output of two coordinated arms (here $Q$ and $R$).

Exercises Intermediate+

Advanced results Master

Theorem 1 (renin — Tigerstedt and Bergman 1898). Robert Tigerstedt and Per Bergman at the Karolinska Institute in Stockholm discovered that an aqueous extract of renal cortex, injected intravenously into a recipient rabbit, produced a sustained rise in blood pressure; they named the active principle renin ^{[Tigerstedt-Bergman 1898]}. The discovery established that the kidney is an endocrine organ as well as an excretory organ, and that a renal factor could regulate the circulation. Tigerstedt and Bergman's 1898 paper in Skandinavisches Archiv für Physiologie (volume 8, pages 223-271) was prescient but largely ignored for thirty years; its findings were resurrected and confirmed after Goldblatt's experimental model put renal hypertension on the map.

Theorem 2 (the Goldblatt clamp — experimental renal hypertension, 1934). Harry Goldblatt at Western Reserve University in Cleveland showed that partial constriction of one renal artery (the "Goldblatt clamp") in a dog produces sustained hypertension within days, with the pressor substance later traced to renal ischemia-driven renin release ^{[Goldblatt 1934]}. The Goldblatt one-kidney-one-clip and two-kidney-one-clip models remain the standard experimental systems for studying renovascular hypertension. The model was the experimental bridge that turned Tigerstedt-Bergman's obscure extract into a clinically recognised mechanism; renovascular hypertension (renal artery stenosis) in humans reproduces the Goldblatt picture and is treated by angioplasty or by RAAS blockade (with care, because ACE inhibition in bilateral renal artery stenosis can precipitate acute kidney injury by removing the Ang-II-mediated efferent-arteriolar constriction that maintains glomerular filtration pressure in the underperfused kidney).

Theorem 3 (hypertensin = angiotensin — Braun-Menéndez 1940 and Page-Helmer 1940). Independently in Buenos Aires and Cleveland, the laboratories of Bernardo Houssay's student Eduardo Braun-Menéndez and of Irvine Page isolated the active pressor substance generated when renin acts on plasma. Braun-Menéndez named it hypertensin; Page named it angiotonin. The two groups agreed in 1958 to coin the term angiotensin and the substrate angiotensinogen to resolve the priority dispute. Braun-Menéndez 1940 ^{[Braun-Menendez 1940]} showed that the active substance was a small peptide generated by enzymatic cleavage, establishing the cascade architecture of the RAAS.

Theorem 4 (Ang I and Ang II separation — Skeggs 1956). Leonard Skeggs and colleagues at the Cleveland Veterans Administration Hospital separated the renin-generated peptide into two fractions by chromatography: an inactive decapeptide (angiotensin I) and an active octapeptide (angiotensin II), and showed that the conversion was catalysed by a plasma "converting enzyme" later named ACE ^{[Skeggs 1956]}. The discovery established the two-step cascade architecture (renin then ACE) that became the framework for all subsequent pharmacology.

Theorem 5 (the Bothrops jararaca venom peptides — Ferreira 1965). Sérgio Ferreira at the Butantan Institute in São Paulo, Brazil, isolated a family of small peptides from the venom of the South American pit viper Bothrops jararaca that potentiated the vasodilator bradykinin, naming the fraction the bradykinin-potentiating factor (BPF) ^{[Ferreira 1965]}. Ferreira travelled to London in 1968 to work with John Vane at the Royal College of Surgeons; Vane and his postdoc Mick Bakhle showed that BPF also inhibited Ang I to Ang II conversion. The dual specificity (BPF inhibits both bradykinin degradation and Ang II generation) revealed that ACE and kininase II are the same enzyme, and provided the molecular template from which the synthetic ACE inhibitors were designed.

Theorem 6 (captopril — the first oral ACE inhibitor, Ondetti-Rubin-Cushman 1977). Miguel Ondetti, Bernard Rubin, and David Cushman at E. R. Squibb & Sons in Princeton designed captopril (1-[(2S)-3-mercapto-2-methylpropionyl]-L-proline) by combining the structure-activity lessons of Ferreira's venom peptides with Byers and Wolfenden's 1973 model of ACE as a zinc metallopeptidase ^{[Ondetti 1977]}. The captopril sulfhydryl chelates the active-site zinc, producing tight competitive inhibition with $K_i\approx 1.7$ nM. Captopril reached the market in 1981, the first orally-active ACE inhibitor, and revolutionised the treatment of hypertension and heart failure. The captopril work is the canonical demonstration of structure-based rational drug design: the venom peptides were read out as a structural template, the active-site zinc was deduced from inhibition kinetics, and the drug was synthesised to fit both constraints. Captopril was followed by enalapril (Patchett 1981, Nature — a longer-acting analog without the sulfhydryl, hence less rash and taste disturbance), lisinopril (Patchett 1980), and ramipril — together the -pril class that has treated more than 200 million hypertensive patients.

Theorem 7 (the volume-versus-vasoconstriction theory — Laragh 1972-73). John Laragh at Cornell-New York Hospital analysed the renin and aldosterone profiles of hypertensive patients and proposed that essential hypertension has two mechanistic subtypes — a vasoconstriction-mediated form driven by Ang II (high-renin, responding to ACE inhibitors, ARBs, or beta-blockers) and a volume-mediated form driven by aldosterone-sodium retention (low-renin, responding to diuretics or MR antagonists) ^{[Laragh 1973]}. The renin-profiling approach to choosing antihypertensive therapy was contested in the 1970s and 1980s (Brunner, Laragh, Baer et al. 1972 — N. Engl. J. Med. 286:441) but the modern framework of heart failure, chronic kidney disease, and resistant-hypertension trials has largely vindicated Laragh's mechanistic distinction: MR antagonists are uniquely effective in resistant hypertension (PATHWAY-2 2015), and ACE inhibitors/ARBs are uniquely renoprotective in proteinuric chronic kidney disease (RENAAL, IDNT, and the long SGLT2-inhibitor programmes that built on the RAAS-blockade foundation).

Theorem 8 (PARADIGM-HF — sacubitril/valsartan, McMurray 2014). John McMurray and colleagues led the PARADIGM-HF trial in 8442 patients with HFrEF, randomising to sacubitril/valsartan (an ARB plus neprilysin inhibitor) versus enalapril (an ACE inhibitor) ^{[McMurray 2014]}. The trial was stopped early for overwhelming benefit: sacubitril/valsartan reduced the primary composite outcome of cardiovascular death or heart-failure hospitalisation by 20 percent versus enalapril (HR 0.80, $P<0.001$), the largest single-trial effect size for a heart-failure therapy in the modern era. Neprilysin is a zinc metallopeptidase that degrades natriuretic peptides (ANP, BNP, CNP), bradykinin, substance P, and Ang II; inhibiting it augments natriuretic signalling (vasodilation, natriuresis, anti-fibrosis) on top of AT1 blockade by the valsartan component. The sacubitril/valsartan combination must not be used within 36 hours of an ACE inhibitor (the resulting bradykinin accumulation produces serious angioedema).

Synthesis. The eight theorems trace the canonical path of an endocrine-physiology system solved at molecular resolution over a century: discovery of the hormone (Tigerstedt-Bergman 1898), the experimental disease model (Goldblatt 1934), isolation of the active peptide (Braun-Menendez 1940, Skeggs 1956), the pharmacological template from nature (Ferreira 1965, Bothrops jararaca), structure-based drug design (Ondetti-Rubin-Cushman 1977, captopril), the mechanistic disease taxonomy (Laragh 1973, volume versus vasoconstriction), and the next-generation combination therapy (McMurray 2014, PARADIGM-HF). The foundational reason the RAAS yields this complete molecular-to-clinical arc is that the cascade architecture — renin, ACE, AT1 receptor, mineralocorticoid receptor — exposes four druggable enzymatic and receptor nodes, each with distinct kinetics, side-effect profiles, and disease-state indications. This is exactly the central insight that distinguishes the RAAS from every other hormonal system in clinical medicine: the same regulated variable (mean arterial pressure) is identified with the joint output of two coordinated arms (vasoconstriction and volume), each druggable separately.

Putting these together generalises the closed-loop framework to every endocrine axis in clinical medicine — the HPA axis (CRH-ACTH-cortisol), the gonadal axis (LH-FSH-sex-steroids), the thyroid HPT axis (TRH-TSH-T3/T4), the calcium-PTH axis — each with a three-tier topology and a peripheral feedback signal. The pattern recurs with the same mechanistic taxonomy: peripheral hormone acts at multiple coordinated end-organs, central suppression closes the loop, and disease arises from over-activation, under-activation, or autonomous-adenoma decoupling. The bridge is the AT1 G-protein-coupled receptor (a canonical seven-transmembrane Gq-coupled receptor of the rhodopsin family), and the bridge appears again in 17.07.01 where the GPCR superfamily is treated in full molecular detail.

Full proof set Master

Proposition 1 (steady-state MAP under dual-arm RAAS control). Let $P^{\ast }$ denote steady-state mean arterial pressure, $A_{\mathrm{Ang}}^{\ast }$ steady-state Ang II concentration, and the closed-loop parameters $\alpha ,\beta ,\gamma ,\delta ,ϵ,A_{\mathrm{base}},Q_0,R_0,V_0,I,E_0$ as defined in the Key mechanism section. Then

$$P^{\ast }(A_{\mathrm{Ang}}^{\ast })=(Q_0+\alpha \gamma N^{\ast }(A_{\mathrm{Ang}}^{\ast }))\cdot R_0(1+\beta A_{\mathrm{Ang}}^{\ast }),$$

where $N^{\ast }$ is set by the steady-state sodium-balance condition $\dot{N}=0$, giving

$$A^{\ast }=\frac{E_0-I}{\delta },A_{\mathrm{Ang}}^{\ast }=\frac{A^{\ast }-A_{\mathrm{base}}}{ϵ},N^{\ast }(A_{\mathrm{Ang}}^{\ast })\text{ determined by }{V}^{\ast }=V_0+\gamma N^{\ast }.$$

Proof. The steady-state sodium-balance condition $\dot{N}=0$ on $\dot{N}=I-E_0+\delta A$ gives $A^{\ast }=(E_0-I)/\delta$. The adrenal-cortex relation $A=A_{\mathrm{base}}+ϵA_{\mathrm{Ang}}$ at steady state gives $A_{\mathrm{Ang}}^{\ast }=(A^{\ast }-A_{\mathrm{base}})/ϵ$. The volume-sodium relation $V=V_0+\gamma N$ at steady state gives $V^{\ast }=V_0+\gamma N^{\ast }$. The Frank-Starling linearisation $Q=Q_0+\alpha (V-V_0)$ at steady state gives $Q^{\ast }=Q_0+\alpha \gamma N^{\ast }$. The Ang-II-vasoconstriction relation $R=R_0(1+\beta A_{\mathrm{Ang}})$ at steady state gives $R^{\ast }=R_0(1+\beta A_{\mathrm{Ang}}^{\ast })$. The systemic-circulation identity $P=Q\cdot R$ at steady state gives $P^{\ast }=Q^{\ast }\cdot R^{\ast }$. Substituting through,

$$P^{\ast }=(Q_0+\alpha \gamma N^{\ast })\cdot R_0(1+\beta A_{\mathrm{Ang}}^{\ast }).\square$$

Proposition 2 (the pharmacological sensitivities — Laragh's framework formalised). The steady-state BP sensitivity to each RAAS-targeting drug class is given by a partial derivative of $P^{\ast }$ with respect to the corresponding closed-loop gain. For an ACE inhibitor that reduces $A_{\mathrm{Ang}}^{\ast }$ by a factor $f\in (0,1)$:

$$\frac{\Delta P^{\ast }}{P^{\ast }}\approx f\cdot (\frac{\beta A_{\mathrm{Ang}}^{\ast }}{1+\beta A_{\mathrm{Ang}}^{\ast }}+\frac{\alpha \gamma ϵA_{\mathrm{Ang}}^{\ast }\cdot \partial N^{\ast }/\partial A_{\mathrm{Ang}}^{\ast }}{Q_0+\alpha \gamma N^{\ast }}).$$

The first term is the vasoconstriction-arm contribution (governed by $\beta$); the second is the volume-arm contribution (governed by $\alpha \gamma ϵ$). The terms decompose the predicted drug response into the Laragh volume-versus-vasoconstriction phenotypes.

Proof. From Proposition 1, $P^{\ast }=Q^{\ast }\cdot R^{\ast }$. Differentiating in log form,

$$\frac{\mathrm{d}{P}^{\ast }}{P^{\ast }}=\frac{\mathrm{d}{Q}^{\ast }}{Q^{\ast }}+\frac{\mathrm{d}{R}^{\ast }}{R^{\ast }}.$$

For the vasoconstriction arm, $\mathrm{d}{R}^{\ast }/R^{\ast }=(\beta /(1+\beta A_{\mathrm{Ang}}^{\ast }))\cdot \mathrm{d}{A}_{\mathrm{Ang}}^{\ast }=(\beta A_{\mathrm{Ang}}^{\ast }/(1+\beta A_{\mathrm{Ang}}^{\ast }))\cdot (\mathrm{d}{A}_{\mathrm{Ang}}^{\ast }/A_{\mathrm{Ang}}^{\ast })$. For the volume arm, $\mathrm{d}{Q}^{\ast }/Q^{\ast }=(\alpha \gamma /Q^{\ast })\cdot \mathrm{d}{N}^{\ast }=(\alpha \gamma ϵA_{\mathrm{Ang}}^{\ast }\cdot \partial N^{\ast }/\partial A_{\mathrm{Ang}}^{\ast })/(Q_0+\alpha \gamma N^{\ast })\cdot (\mathrm{d}{A}_{\mathrm{Ang}}^{\ast }/A_{\mathrm{Ang}}^{\ast })$. Adding and substituting $\mathrm{d}{A}_{\mathrm{Ang}}^{\ast }/A_{\mathrm{Ang}}^{\ast }=-f$ for an ACE-inhibitor-induced fractional reduction $f$ in $A_{\mathrm{Ang}}^{\ast }$, the result follows. $\square$

A high-renin phenotype (large $\beta A_{\mathrm{Ang}}^{\ast }$ relative to baseline) yields a large vasoconstriction-arm contribution and an ACE-inhibitor-induced BP reduction dominated by $\beta$. A low-renin, high-aldosterone phenotype (large $\delta A^{\ast }$ with $A_{\mathrm{Ang}}^{\ast }$ nearly suppressed) yields a small vasoconstriction-arm contribution but a volume-arm contribution that is refractory to ACE inhibition (because aldosterone is decoupled from Ang II); an MR antagonist is the appropriate therapy in this phenotype. The two terms are pharmacologically independent, supporting Laragh's recommendation to choose drug class by renin-aldosterone profile.

Connections Master

• Renal physiology — homeostasis and the nephron 18.08.01. The chapter survey introduces the kidney's filtration-reabsorption-secretion architecture and the homeostatic control of extracellular-fluid volume. The current unit deepens that framework at the level of the kidney's blood-pressure-sensing mechanism: the juxtaglomerular apparatus is the sensory organ that closes the RAAS feedback loop, integrating renal perfusion pressure, macula-densa NaCl delivery, and sympathetic input into a single renin-secretion output. Cross-reference flows both ways — 18.08.01 cites the RAAS as the canonical long-term BP regulator; the current unit provides the mechanistic depth at every enzymatic and receptor node.

• Cardiovascular physiology — the heart 18.02.01 and hemodynamics 18.02.03 pending. The dual-arm closed-loop model in this unit builds on the $P=Q\cdot R$ identity established in the hemodynamics peer, where Poiseuille-derived vascular resistance is treated in mechanical terms and cardiac output is decomposed into stroke volume and heart rate. The RAAS acts on both arms of that identity — Ang II on $R$ (vasoconstriction) and aldosterone on $Q$ (volume expansion via venous return and Frank-Starling). The cardiac and renal systems share the BP-regulation axis, and hypertension is the disease of chronic RAAS over-activation that drives both the cardiac (left-ventricular hypertrophy, heart failure with reduced ejection fraction) and the renal (proteinuria, chronic kidney disease) complications.

• Cardiac action potentials, pacemaker physiology, and the ECG 18.02.02. The ECG is the most accessible marker of hypertensive heart disease — left-ventricular hypertrophy (Cornell voltage criteria, Sokolow-Lyon criteria), left atrial enlargement, and the secondary ST-T changes of strain are the direct electrical signature of chronic RAAS-driven pressure overload on the left ventricle. RAAS blockade (ACE inhibitors, ARBs, MR antagonists, sacubitril/valsartan) produces regression of left-ventricular hypertrophy measurable on serial ECGs over 6 to 12 months of therapy, a clinical surrogate for the cardiac-remodelling benefit demonstrated in outcome trials (LIFE 2002, valsartan versus atenolol).

• Thyroid hormones and the HPT axis 18.07.04. The HPT axis (TRH-TSH-T3/T4 with negative feedback) is the canonical endocrine feedback loop against which the RAAS is compared: both systems have a three-tier topology, both act at a G-protein-coupled membrane receptor at the second tier, and both require a peripheral-activation step (Ang I to Ang II by ACE for the RAAS; T4 to T3 by deiodinases for the thyroid). The two axes operate on different time scales (minutes for the RAAS, hours to days for the thyroid) and through different terminal receptors (AT1 GPCR versus nuclear thyroid receptor), but the closed-loop-control architecture is the same. The dual-axis framework introduced here also sets the stage for the HPA axis (CRH-ACTH-cortisol) and the gonadal axis in subsequent endocrinology units.

• Cell signalling: receptors and GPCRs 17.07.01. The AT1 receptor is a canonical seven-transmembrane G-protein-coupled receptor of the rhodopsin family, signalling through Gq/11 (phospholipase C, IP3, intracellular Ca2+ in vascular smooth muscle) and coupling through Gi/o for sympathetic facilitation. The molecular-cell-biology peer provides the structural and mechanistic framework — GPCR topology, G-protein coupling specificity, second-messenger cascades, receptor desensitisation and internalisation — on which the RAAS acts. The AT2 receptor, in contrast, signals through Gi and bradykinin/nitric-oxide vasodilation, the counter-regulatory arm whose existence was a major pharmacological rationale for ARBs over ACE inhibitors (AT2 remains unblocked when AT1 is antagonised).

Historical & philosophical context Master

The renin-angiotensin-aldosterone system was solved over a century of incremental work that began with a curious kidney extract and culminated in the largest drug class in modern cardiovascular medicine. Robert Tigerstedt and his student Per Bergman at the Karolinska Institute in Stockholm showed in 1898 that an aqueous extract of renal cortex (but not renal medulla) injected intravenously into a recipient rabbit produced a sustained rise in blood pressure; they named the active principle renin ^{[Tigerstedt-Bergman 1898]}. The Tigerstedt-Bergman paper in Skandinavisches Archiv für Physiologie (volume 8, pages 223-271) was largely ignored for thirty years — the contemporary establishment did not believe the kidney was an endocrine organ — until Harry Goldblatt at Western Reserve University in Cleveland showed in 1934 that partial constriction of a renal artery in the dog produced sustained hypertension by releasing renin from the ischaemic kidney ^{[Goldblatt 1934]}. Goldblatt's "clamp" model in J. Exp. Med. 59:347 turned Tigerstedt-Bergman's obscure extract into a clinically recognised mechanism and remains the standard experimental system for renovascular hypertension.

The molecular identification of the cascade followed over thirty years. Eduardo Braun-Menéndez in Buenos Aires and Irvine Page in Cleveland independently isolated the active pressor peptide generated when renin acts on plasma — Braun-Menéndez naming it hypertensin, Page naming it angiotonin; the two groups agreed in 1958 on the term angiotensin and the substrate angiotensinogen ^{[Braun-Menendez 1940]}. Leonard Skeggs and colleagues at the Cleveland Veterans Administration Hospital separated the renin-generated peptide into the inactive decapeptide angiotensin I and the active octapeptide angiotensin II by chromatography in 1956 ^{[Skeggs 1956]}, establishing the two-step cascade architecture and identifying the converting enzyme. The Gross 1958 demonstration that aldosterone secretion is stimulated by angiotensin II closed the renal-adrenal loop and named the system as we now know it — the renin-angiotensin-aldosterone system. The Aldosterone isolation work of Simpson and Tait (1952-1955) and the structure elucidation by Reichstein and Wettstein ran in parallel.

The pharmacological revolution began in the unlikeliest of places. Sérgio Ferreira at the Butantan Institute in São Paulo, Brazil, studying the venom of the jararaca snake (Bothrops jararaca) in 1965, isolated a family of small peptides that potentiated the vasodilator bradykinin — the bradykinin-potentiating factor (BPF) ^{[Ferreira 1965]}. John Vane and Mick Bakhle at the Royal College of Surgeons in London showed in 1968 that BPF also inhibited Ang I to Ang II conversion, revealing that ACE and kininase II are the same enzyme. Miguel Ondetti, Bernard Rubin, and David Cushman at E. R. Squibb & Sons in Princeton used the structure of Ferreira's venom peptides plus Byers-Wolfenden's 1973 zinc-metallopeptidase model of ACE to design captopril — a small, orally-active, sulfhydryl-containing molecule that chelates the ACE active-site zinc with $K_i$ of 1.7 nM ^{[Ondetti 1977]}. Captopril reached market in 1981 and was followed within a decade by enalapril and lisinopril (Patchett 1980-81, Nature 288:280) — together the -pril class that has treated more than 200 million hypertensive patients.

The losartan work of Timmermans and colleagues at Du Pont (Duncia, Carini, Chiu et al., 1990; losartan approved by the FDA in 1995 as the first nonpeptide ARB) opened the -sartan class, and McMurray's PARADIGM-HF trial of sacubitril/valsartan in 2014 ^{[McMurray 2014]} introduced the ARB-plus-neprilysin-inhibitor combination that is now first-line therapy in heart failure with reduced ejection fraction. The discovery by Hoffmann and colleagues in 2020 (Cell 181:1481) that SARS-CoV-2 uses ACE2 for cell entry re-opened the RAAS literature to a global audience and raised — then resolved — the question of whether ACE inhibitors and ARBs worsen COVID-19 outcomes (large cohort studies confirmed they do not, and may be protective). The same molecular cascade Tigerstedt-Bergman opened in 1898 remains, in 2026, the most actively studied hormonal system in clinical medicine.

Bibliography Master

Primary literature.

@article{TigerstedtBergman1898,
  author = {Tigerstedt, R. and Bergman, P. G.},
  title = {Niere und Kreislauf},
  journal = {Skand. Arch. Physiol.},
  volume = {8},
  year = {1898},
  pages = {223--271},
}

@article{Goldblatt1934,
  author = {Goldblatt, H. and Lynch, J. and Hanzal, R. F. and Summerville, W. V.},
  title = {Studies on experimental hypertension: {I}. The production of persistent elevation of systolic blood pressure by means of renal ischemia},
  journal = {J. Exp. Med.},
  volume = {59},
  year = {1934},
  pages = {347--379},
}

@article{BraunMenendez1940,
  author = {Braun-Menendez, E. and Fasciolo, J. C. and Leloir, L. F. and Munoz, J. M. and Taquini, A. C.},
  title = {Renal hypertension},
  journal = {J. Physiol. (Lond.)},
  volume = {98},
  year = {1940},
  pages = {283--298},
}

@article{Skeggs1956,
  author = {Skeggs, L. T. and Kahn, J. R. and Shumway, N. P.},
  title = {The preparation and function of the hypertensin-converting enzyme},
  journal = {J. Exp. Med.},
  volume = {103},
  year = {1956},
  pages = {295--299},
}

@article{Gross1958,
  author = {Gross, F.},
  title = {Renin und Hypertensin, physiologische oder pathologische Wirkstoffe},
  journal = {Klin. Wochenschr.},
  volume = {36},
  year = {1958},
  pages = {693--706},
}

@article{Ferreira1965,
  author = {Ferreira, S. H.},
  title = {A bradykinin-potentiating factor ({BPF}) present in the venom of \textit{Bothrops jararaca}},
  journal = {Br. J. Pharmacol. Chemother.},
  volume = {24},
  year = {1965},
  pages = {163--169},
}

@article{Ondetti1977,
  author = {Ondetti, M. A. and Rubin, B. and Cushman, D. W.},
  title = {Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents},
  journal = {Science},
  volume = {196},
  year = {1977},
  pages = {441--444},
}

@article{Patchett1980,
  author = {Patchett, A. A. and Harris, E. and Tristram, E. W. and Wyvratt, M. J. and Wu, M. T. and Taub, D. and others},
  title = {A new class of angiotensin-converting enzyme inhibitors},
  journal = {Nature},
  volume = {288},
  year = {1980},
  pages = {280--283},
}

@article{Laragh1973,
  author = {Laragh, J. H.},
  title = {Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles},
  journal = {Am. J. Med.},
  volume = {55},
  year = {1973},
  pages = {261--274},
}

@article{Brunner1972,
  author = {Brunner, H. R. and Laragh, J. H. and Baer, L. and Newton, M. A. and Goodwin, F. T. and Krakoff, L. R. and Bard, R. H. and Buhler, F. R.},
  title = {Essential hypertension: renin and aldosterone, heart attack and stroke},
  journal = {N. Engl. J. Med.},
  volume = {286},
  year = {1972},
  pages = {441--449},
}

@article{Timmermans1993,
  author = {Timmermans, P. B. M. W. M. and Wong, P. C. and Chiu, A. T. and Herblin, W. F. and Benfield, P. and Carini, D. J. and Lee, R. J. and Wexler, R. R. and Saye, J. A. M. and Smith, R. D.},
  title = {Angiotensin {II} receptors and angiotensin {II} receptor antagonists},
  journal = {Pharmacol. Rev.},
  volume = {45},
  year = {1993},
  pages = {205--251},
}

@article{McMurray2014,
  author = {McMurray, J. J. V. and Packer, M. and Desai, A. S. and Gong, J. and Lefkowitz, M. P. and Rizkala, A. R. and Rouleau, J. L. and Shi, V. C. and Solomon, S. D. and Swedberg, K. and Zile, M. R.},
  title = {Angiotensin-neprilysin inhibition versus enalapril in heart failure ({PARADIGM-HF})},
  journal = {N. Engl. J. Med.},
  volume = {371},
  year = {2014},
  pages = {993--1004},
}

@article{Hoffmann2020,
  author = {Hoffmann, M. and Kleine-Weber, H. and Schroeder, S. and Kruger, N. and Herrler, T. and Erichsen, S. and Schiergens, T. S. and Herrler, G. and Wu, N.-H. and Nitsche, A. and Muller, M. A. and Drosten, C. and Pohlmann, S.},
  title = {SARS-{CoV}-2 cell entry depends on {ACE2} and {TMPRSS2} and is blocked by a clinically proven protease inhibitor},
  journal = {Cell},
  volume = {181},
  year = {2020},
  pages = {1481--1492},
}

@article{RALES1999,
  author = {Pitt, B. and Zannad, F. and Remme, W. J. and Cody, R. and Castaigne, A. and Perez, A. and Palensky, J. and Wittes, J.},
  title = {The effect of spironolactone on morbidity and mortality in patients with severe heart failure ({RALES})},
  journal = {N. Engl. J. Med.},
  volume = {341},
  year = {1999},
  pages = {709--717},
}

@article{PATHWAY2_2015,
  author = {Williams, B. and MacDonald, T. M. and Morant, S. and Webb, D. J. and Sever, P. and McInnes, G. and Ford, I. and Cruickshank, J. K. and Caulfield, M. J. and Salsbury, J. and Mackenzie, I. and Padmanabhan, N. and Brown, M. J.},
  title = {Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension ({PATHWAY-2})},
  journal = {Lancet},
  volume = {386},
  year = {2015},
  pages = {2059--2068},
}

Textbook and monograph.

@book{BoronBoulpaep2017,
  author = {Boron, W. F. and Boulpaep, E. L.},
  title = {Medical Physiology},
  edition = {3rd},
  publisher = {Elsevier},
  year = {2017},
}

@book{GuytonHall2021,
  author = {Hall, J. E. and Hall, M. E.},
  title = {Guyton and Hall Textbook of Medical Physiology},
  edition = {14th},
  publisher = {Elsevier},
  year = {2021},
}

@book{BrennerRector2020,
  editor = {Yu, A. S. L. and Chertow, G. M. and Luyckx, V. A. and Marsden, P. A. and Skorecki, K. and Taal, M. W.},
  title = {Brenner and Rector's The Kidney},
  edition = {11th},
  publisher = {Elsevier},
  year = {2020},
}

@book{Braunwald2019,
  editor = {Zipes, D. P. and Libby, P. and Bonow, R. O. and Mann, D. L. and Tomaselli, G. F. and Braunwald, E.},
  title = {Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine},
  edition = {11th},
  publisher = {Elsevier},
  year = {2019},
}